MT-8421 is under clinical development by Molecular Templates and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC). According to GlobalData, Phase I drugs for Head And Neck Squamous Cell Carcinoma (HNSC) have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MT-8421’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MT-8421 overview

Fusion proteins are under development for the treatment of solid tumors, metastatic melanoma, hepatocellular carcinoma, non-small cell cancer, renal cell carcinoma, urothelial carcinoma, esophageal squamous cell carcinoma, mesothelioma, head and neck squamous cell carcinoma and cervical cancer. They act by targeting cytotoxic T lymphocyte associated antigen 4. They comprise of immunoglobulin-targeting domain fused with a genetically engineered form of Shiga-like Toxin A (SLTA). The drug candidates are being developed based on ETB (engineered toxin bodies) platform. It is administered through intravenous route.

Molecular Templates overview

Molecular Templates, Inc. (Molecular Templates) is a biopharmaceutical company primarily focused on the development of novel therapies for oncology. The company’s proprietary biologic-engineered toxin body (ETB) drug platform is designed to target and destroy cells through unique mechanisms of action. MTI’s pipeline products include MT-6402, MT-8421, and MT-0169. MT-6402 is a third-generation ETB targeting PD-L1, with enhanced internalization and de-immunization. It utilizes antigen seeding technology to deliver a viral antigen. MT-8421 is being developed for targeting CTLA-4-expressing Tregs in the tumor microenvironment for cancer treatment. MT-0169 is being developed for the treatment of multiple myeloma. MTI is headquartered in Austin, Texas, the US.

For a complete picture of MT-8421’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.